CVRx (CVRX) Projected to Post Quarterly Earnings on Monday

CVRx (NASDAQ:CVRX) is expected to be posting its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.5043) per share and revenue of $14.49 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings data on Thursday, February 12th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). The company had revenue of $16.02 million during the quarter, compared to analysts’ expectations of $15.75 million. CVRx had a negative return on equity of 99.32% and a negative net margin of 94.10%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Stock Down 2.4%

Shares of CVRx stock traded down $0.20 on Monday, hitting $7.78. The company had a trading volume of 53,745 shares, compared to its average volume of 331,838. The stock has a market capitalization of $205.49 million, a price-to-earnings ratio of -3.79 and a beta of 0.90. CVRx has a 1 year low of $4.30 and a 1 year high of $11.30. The stock has a 50 day moving average of $8.02 and a 200-day moving average of $8.10. The company has a debt-to-equity ratio of 1.26, a quick ratio of 6.72 and a current ratio of 7.63.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on CVRX shares. Cantor Fitzgerald raised CVRx to a “strong-buy” rating in a report on Tuesday, February 17th. Canaccord Genuity Group restated a “buy” rating and set a $10.00 target price on shares of CVRx in a research report on Tuesday, April 14th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.50.

Insider Activity

In other news, Director Mudit K. Jain purchased 46,800 shares of the stock in a transaction on Friday, February 20th. The shares were acquired at an average price of $6.36 per share, for a total transaction of $297,648.00. Following the completion of the transaction, the director directly owned 980,183 shares of the company’s stock, valued at approximately $6,233,963.88. This trade represents a 5.01% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Company insiders own 18.90% of the company’s stock.

Institutional Investors Weigh In On CVRx

Large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in CVRx during the fourth quarter valued at about $79,000. Corient Private Wealth LLC purchased a new stake in CVRx during the fourth quarter valued at about $81,000. XTX Topco Ltd purchased a new stake in CVRx during the fourth quarter valued at about $90,000. Alliancebernstein L.P. grew its stake in shares of CVRx by 10.7% during the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock valued at $142,000 after buying an additional 1,700 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of CVRx by 61.3% during the fourth quarter. Wells Fargo & Company MN now owns 20,266 shares of the company’s stock valued at $144,000 after buying an additional 7,705 shares during the last quarter. Hedge funds and other institutional investors own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.